Follow-up to REDUCE study shows low rate of prostate cancer diagnosis
The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged ...
Jan 22, 2013
0
0